$0.92
+0.06 (+7.39%)
Open$0.84
Previous Close$0.86
Day High$0.93
Day Low$0.84
52W High$29.62
52W Low$16.04
Volume—
Avg Volume420.0K
Market Cap9.90M
P/E Ratio53.69
EPS$0.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,444.2% upside
Current
$0.92
$0.92
Target
$32.61
$32.61
$25.28
$32.61 avg
$46.79
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.43M | 2.52M | 2.31M |
| Net Income | 150.5K | 215.1K | 194.2K |
| Profit Margin | 6.2% | 8.5% | 8.4% |
| EBITDA | 295.2K | 302.7K | 296.9K |
| Free Cash Flow | 147.2K | 165.8K | 140.8K |
| Rev Growth | +21.7% | -7.9% | -0.3% |
| Debt/Equity | 0.76 | 0.80 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |